Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Douglas A. McIntyre | May 24, 2007 at 7:08 AM EDT

Dendreon Downgraded by JMP Securities (DNDN)

Dendreon Corp. (DNDN-NASDAQ) was downgraded from an “Outperform” rating to a “Market Perform” rating. The brokerage sees uncertainties and risks…

Douglas A. McIntyre | May 23, 2007 at 8:14 AM EDT

Cypress Biosciences & Forest Labs Get a Newer Boost, An Understatement (CYPB, FRX)

Cypress Biosciences (CYPB-NASDAQ) is literally a ‘double" in pre-market trading. Forest Labs (FRX-NYSE) and the company released top-line Phase III…

Douglas A. McIntyre | May 23, 2007 at 7:49 AM EDT

Northfield Labs Heads Permanently South

Northfield Labs (NFLD-NASDAQ) just faced what may the knockout blow for the company. The company has been working for years…

Douglas A. McIntyre | May 22, 2007 at 4:36 PM EDT

Short Selling Up in Drug & Medical Stocks

Some sectors showed mixed results in the short selling, but the Big Pharma and medical instruments and related companies saw…

Douglas A. McIntyre | May 22, 2007 at 3:13 PM EDT

Medtronic Indicated Higher on Earnings (MDT)

Medtronic (MDT-NYSE) posted quarterly results with revenues up 75 to $3.28 Billion, helped on currency by $71 million. Net earnings…

Douglas A. McIntyre | May 22, 2007 at 10:02 AM EDT

Dendreon Interest Remains Extremely High

Since Dendreon (DNDN) has gotten a bit of life this week, there have been numerous inquiries as to "Where is…

Douglas A. McIntyre | May 21, 2007 at 10:33 AM EDT

Antigenics’ Oncophage Data Boosts Shares

Antigenics (AGEN-NASDAQ) saw its shares pop more than 20% as it released data in apress release regarding its Oncophage trials.…

Douglas A. McIntyre | May 21, 2007 at 6:53 AM EDT

Dendreon’s New Double-Twist

Dendreon (DNDN-NASDAQ) has an interesting twist this morning because of two issues. Yesterday it announced some new study data on…

Douglas A. McIntyre | May 16, 2007 at 1:40 PM EDT

The Value of Psoriasis Treatments (CGPI)

This morning there was a micro-cap biotech that focuses primarily on dermatological issues, made what could be an interesting acquisition…

Douglas A. McIntyre | May 15, 2007 at 8:04 AM EDT

Dendreon, the Day That Could Have Been and What to Expect Now

At about 5:20 this morning after rolling the calendar a day over to see the notes, something stood out like…

Douglas A. McIntyre | May 15, 2007 at 7:13 AM EDT

Myriad’s Alarming Alzheimer’s Forecasts

Myriad Genetics, Inc. (MYGN-NASDAQ) has issued a press release discussing a new study showing that the potential savings to the…

Douglas A. McIntyre | May 14, 2007 at 11:21 AM EDT

Mylan’s Shareholders Act As LBO Lenders

Mylan Labs (MYL-NYSE) is seeing its shares take a beating because it is acquiring Merck KGaA’s generic unit and Mylan…

Douglas A. McIntyre | May 12, 2007 at 10:00 AM EDT

Friday’s Top Biotech & Medical Stocks

by H.S. AyoubBioHealth Investor.com Biotechnology DENDREON CORP [DNDN] +10.29% NORTHFIELD LABS IN [NFLD] +10.25% COMBINATORX [CRXX] +9.56% ONYX PHARM INC…

Douglas A. McIntyre | May 12, 2007 at 9:59 AM EDT

IBD Weekly Top Ranked Medical Stocks

From BioHealth Investor The following list represents the top ten medical stocks ranked according to Earnings Per Share and Relative…

Douglas A. McIntyre | May 10, 2007 at 4:30 PM EDT

Comments From Dendreon’s Conference Call (May 10, 2007)

Dendreon hosted a painful conference call today, and despite management answering most questions you could hear some frustration and disappointment…

1 … 369 370 371 372 373 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Dendreon Downgraded by JMP Securities (DNDN)

Cypress Biosciences & Forest Labs Get a Newer Boost, An Understatement (CYPB, FRX)

Northfield Labs Heads Permanently South

Short Selling Up in Drug & Medical Stocks

Medtronic Indicated Higher on Earnings (MDT)

Dendreon Interest Remains Extremely High

Antigenics’ Oncophage Data Boosts Shares

Dendreon’s New Double-Twist

The Value of Psoriasis Treatments (CGPI)

Dendreon, the Day That Could Have Been and What to Expect Now

Myriad’s Alarming Alzheimer’s Forecasts

Mylan’s Shareholders Act As LBO Lenders

Friday’s Top Biotech & Medical Stocks

IBD Weekly Top Ranked Medical Stocks

Comments From Dendreon’s Conference Call (May 10, 2007)

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Health and Healthcare Articles

All Health and Healthcare Articles

Dendreon Downgraded by JMP Securities (DNDN)

Cypress Biosciences & Forest Labs Get a Newer Boost, An Understatement (CYPB, FRX)

Northfield Labs Heads Permanently South

Short Selling Up in Drug & Medical Stocks

Medtronic Indicated Higher on Earnings (MDT)

Dendreon Interest Remains Extremely High

Antigenics’ Oncophage Data Boosts Shares

Dendreon’s New Double-Twist

The Value of Psoriasis Treatments (CGPI)

Dendreon, the Day That Could Have Been and What to Expect Now

Myriad’s Alarming Alzheimer’s Forecasts

Mylan’s Shareholders Act As LBO Lenders

Friday’s Top Biotech & Medical Stocks

IBD Weekly Top Ranked Medical Stocks

Comments From Dendreon’s Conference Call (May 10, 2007)

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%